Atlas
Back to Pharma Services
Peer Fund / Dealmaker·Pharma Services

Maneet Singh

Managing Director and Co-Head of Healthcare M&A Investment Banking at Barclays

New York, NY, USA

MS
LinkedIn
Why they matter

Co-runs Barclays' US healthcare M&A practice and just worked the Avidity–Novartis deal, giving him live visibility into biopharma and pharma-services deal flow and pricing.

Background

Maneet Singh is a Managing Director and Co-Head of Healthcare M&A Investment Banking at Barclays, based in New York, jointly leading the firm's US healthcare advisory practice since joining in September 2023. He previously spent his career as a Managing Director in the Healthcare Group at Goldman Sachs and in the M&A Group at Credit Suisse, advising large and mid-cap biopharma companies on major transactions. He holds an MBA from NYU's Stern School of Business and a BA from Johns Hopkins University.

Notable deals

  • 2023
    Recruited by Barclays as Managing Director and Co-Head of Healthcare M&A Investment Banking, part of a senior build-out of the bank's healthcare/biopharma advisory franchise
  • 2025
    Barclays (alongside Goldman Sachs) served as financial advisor to Avidity Biosciences on its ~$12 billion acquisition by Novartis

Call-prep brief

Background

  • MD and Co-Head of Healthcare M&A Investment Banking at Barclays (since Sept 2023), based in New York
  • Prior MD roles at Goldman Sachs (Healthcare Group) and Credit Suisse (M&A Group)
  • MBA, NYU Stern; BA, Johns Hopkins University

Current focus

  • Co-leads Barclays' US healthcare advisory coverage alongside the firm's biopharma banking team
  • Was one of Barclays' advisors on Avidity Biosciences' ~$12B sale to Novartis (2025), giving him a fresh read on large-cap pharma appetite for pipeline/platform acquisitions
  • Publicly speaks to M&A drivers in the sector, including loss-of-exclusivity pressure pushing large pharma to acquire

What he cares about

  • Deal flow and positioning within a competitive bank league table (Barclays rebuilt its healthcare IB team in 2023 and is still proving itself against bulge-bracket incumbents)
  • Client relationships with biopharma and pharma-services corporates and boards, not just financial sponsors

Sensitivities

  • Still relatively new at Barclays (under 3 years) — may be cautious about disclosing anything client-confidential or pipeline-related
  • As a sell-side banker, he won't discuss specific unannounced processes or valuation views tied to live mandates

Questions to ask

  1. What's driving strategic buyer appetite for pharma services/CDMO assets right now versus straight biopharma pipeline deals?
  2. Since the Avidity/Novartis deal, has large-pharma willingness to pay up for de-risked, late-stage platforms changed?
  3. Where are valuation gaps between buyers and sellers widest in pharma services right now, and what's closing them?

Outreach draft

Subject
Quick take on pharma services M&A trends
Hi Maneet, I'm on the deal team at a private equity firm building a view on pharma services and CDMO M&A. Your work co-leading Barclays' healthcare M&A practice, including the recent Avidity/Novartis transaction, would give us a valuable read on where strategic and sponsor demand is heading in this space. Would you be open to a 30-minute call in the next couple of weeks to share your perspective on deal activity, valuation trends, and what's driving buyer appetite for pharma services assets? Happy to work around your schedule. Thanks, [Placeholder Name]

Linked companies

Sources